Comparison. Research use only.
TB-500 vs GHK-Cu
TB-500 and GHK-Cu both appear in wound-healing and tissue-repair research, and both are often discussed as if their evidence were equivalent. It is not. TB-500 is a seven-residue fragment of thymosin beta-4 whose biology was mostly established with the full parent protein, while GHK-Cu is a naturally occurring copper-binding tripeptide studied directly in fibroblast culture and topical cosmetic trials.
What is the difference between TB-500 and GHK-Cu?
TB-500 is a synthetic seven-residue fragment of thymosin beta-4 (Ac-LKKTETQ), whose parent protein sequesters G-actin and influences cell migration. GHK-Cu is a naturally occurring tripeptide-copper complex that delivers copper to collagen-related enzymes. Most TB-500 biology was generated with the full-length parent protein and no human trials exist, while GHK-Cu was studied directly, including a topical cosmetic trial in humans.
| Attribute | TB-500 | GHK-Cu |
|---|---|---|
| Identity | Acetylated thymosin beta-4 fragment, residues 17-23 (Ac-LKKTETQ; Esposito et al., 2012) | Glycyl-L-histidyl-L-lysine bound to copper(II) (Gly-His-Lys · Cu) |
| Length | 7 amino acids (parent protein is 43 residues) | 3 amino acids plus a copper ion |
| Molecular weight | 889.0 g/mol | 403.93 Da |
| Origin | Synthetic fragment of an intracellular protein | Occurs naturally in human plasma; first isolated by Pickart and Thaler (1973) |
| Proposed mechanism | Parent protein binds G-actin one-to-one, buffering actin polymerization and cell movement | Copper chaperone to lysyl oxidase, SOD1 and cytochrome c oxidase; collagen I, III and VI synthesis |
| What the evidence was generated with | Mostly the full-length parent protein, not the fragment | GHK-Cu itself, in cell culture, gene-expression and topical studies |
| Human evidence | None; no product in the family has completed a successful Phase 3 program | Topical cosmetic double-blind study (Leyden et al., 2005, n=67) |
| WADA | Prohibited (S2) at all times | Not on the WADA prohibited list |
What is TB-500?
The full-length parent protein from which TB-500 is derived is the main peptide inside eukaryotic cells that sequesters G-actin, meaning it holds single actin units in reserve so they are not built into filaments. It binds monomeric G-actin one-to-one through a conserved actin-binding motif.
Read the full TB-500 research summary →What is GHK-Cu?
GHK-Cu (glycyl-L-histidyl-L-lysine copper(II)) is a naturally occurring copper-binding tripeptide, first isolated from human plasma albumin by Pickart and Thaler in 1973. It is present at concentrations of ~200 ng/mL in plasma of young adults, and declines substantially with age.
Read the full GHK-Cu research summary →TB-500 and GHK-Cu specifications
Frequently asked questions
Do TB-500 and GHK-Cu work through the same mechanism?
No. TB-500 derives from thymosin beta-4, a protein that binds monomeric G-actin one-to-one and buffers the actin pool that governs cell movement. GHK-Cu's activity depends on its bound copper ion: the complex delivers copper to enzymes such as lysyl oxidase and superoxide dismutase, and in fibroblast culture it increased collagen synthesis (Pickart et al., 2015). Both appear in tissue-repair research through unrelated pathways.
Was the research on TB-500 done with TB-500 itself?
Mostly not. Analytical work (Esposito et al., 2012) characterized material sold as TB-500 as the acetylated 17-23 fragment of thymosin beta-4, but essentially all published thymosin beta-4 biology, including cardiac ILK activation (Bock-Marquette et al., Nature 2004), used the full 43-residue protein. GHK-Cu's findings, by contrast, were generated with GHK-Cu itself, from fibroblast culture to topical studies.
Have TB-500 or GHK-Cu been studied in humans?
No human trials of TB-500 appear in our research data, and no product in the thymosin beta-4 family has completed a successful Phase 3 program. GHK-Cu has limited human data, all topical: a double-blind cosmetic study (Leyden et al., 2005, n=67) reported changes in skin elasticity. Neither TB-500 nor GHK-Cu has an approved therapeutic indication outside cosmetics.
What is the regulatory status of TB-500 and GHK-Cu?
TB-500 is not approved by the FDA for any indication, and WADA lists it under section S2, prohibited at all times. GHK-Cu is widely used in topical cosmetic formulations, has no approved therapeutic indication outside cosmetics, and does not appear on the WADA prohibited list. Veridian supplies both TB-500 and GHK-Cu strictly for laboratory research.
Other research peptide comparisons
Both compounds in stock at Veridian. 99%+ HPLC purity, same-day US shipping.
Browse all research peptides →